Licensed Compound to RS BioTherapeutics
Not specified
Pre-clinical or early clinical (inferred from license)Active
Key Facts
Indication
Not specified
Phase
Pre-clinical or early clinical (inferred from license)
Status
Active
Company
About Synthonics
Synthonics is a private, pre-revenue biotech firm founded in 2018 and headquartered in Blacksburg, Virginia, with a focus on small molecule drug development. The company's core technology involves chelating metal ions to known drug compounds to create novel Metal Coordinated Pharmaceuticals (MCPs) with superior absorption and efficacy profiles. With an initial patent granted in 2010 and a growing IP portfolio, Synthonics has demonstrated proof-of-concept in human studies and has entered into its first licensing agreement. The company operates in the niche but promising field of metallodrugs, seeking to overcome limitations of traditional organic pharmaceuticals.
View full company profileOther Not specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |